Abstract
New Breast Cancer Therapies Focus on Improved Efficacy and Reduced Toxicity to
Boost Uptake
The growing incidence of breast cancer among women worldwide highlights the
huge commercial potential for breast cancer therapeutics. To serve this
continual and increasing patient population, it is necessary to launch
innovative products that overcome the significant side effects -- such as
anemia and alopecia -- of prevailing treatments. The need is to develop a
drug, which convinces the consumer of the competitive price, with increase
survival time, low hospital costs, and easy reimbursement schemes. The main
challenge is to reduce toxicity and improve efficacy in the new drug.
This Frost & Sullivan research service examines the global breast cancer
therapeutics market. The study also provides insights into adjuvant products,
cytotoxic, hormonal, and biologic sectors. It details industry challenges, and
market drivers and restraints while giving an overview of the market revenues
and shares.
New Indications for Adjuvant Products Drive Market Growth
Since breast cancer is a multifactor disease, no standardized medication is
available to patients. This malignancy calls for a personalized treatment
often used as an adjuvant setting or as a preventive measure. Besides
mastectomy and radiotherapy, administration of therapeutics such as hormonal,
cytotoxic, or biologic is used to improve the long-term outlook of the
treatment.
"Efforts are being made across the industry to investigate the application of
breast cancer therapies in an adjuvant setting and to obtain approval for
using existing therapeutics of similar cancer indications to treat breast
cancer," says the analyst of this study. Thus, the wider use of more
combination therapies and early diagnosis system is likely to further spur
market growth.
Successful Drug Development Ensures Sustained Growth of Breast Cancer
Therapeutics Market
Market dynamics are set to change with generic companies entering the market.
The most successful participants are the ones that collaborate with drug
innovators to bring out new products. On the strength of these strategic
partnerships the breast cancer therapeutics market is expected to grow at a
compound annual growth rate (CAGR) of 9.8 percent between 2004 and 2011.
The strongest growth is anticipated in the biologics sector, where only one
product, Herceptin is currently available. "Expansion of Herceptin for new
areas of breast cancer and as a preventative measure, as well as for the
approval of other existing therapies for new breast cancer indications can
further drive this sector," concludes the analyst.
| 
View Cart
